Welcome to the new Cancer Discovery website! Learn more about the exciting new features of the platform.
- ReviewsClaudio Vernieri, Stefano Casola, Marco Foiani, Filippo Pietrantonio, Filippo de Braud and Valter LongoCancer Discov December 1 2016 6 (12) 1315-1333; DOI:10.1158/2159-8290.CD-16-0615
- Research BriefsMagda Bahcall, Taebo Sim, Cloud P. Paweletz, Jyoti D. Patel, Ryan S. Alden, Yanan Kuang, Adrian G. Sacher, Nam Doo Kim, Christine A. Lydon, Mark M. Awad, Michael T. Jaklitsch, Lynette M. Sholl, Pasi A. Jänne and Geoffrey R. OxnardCancer Discov December 1 2016 6 (12) 1334-1341; DOI:10.1158/2159-8290.CD-16-0686
A patient with NSCLC responded to a type II MET inhibitor in combination with an EGFR TKI after acquisition of a METD1228V mutation conferred resistance to a type I MET inhibitor.
- Research ArticlesJing Liu, Stephen J. Blake, Michelle C.R. Yong, Heidi Harjunpää, Shin Foong Ngiow, Kazuyoshi Takeda, Arabella Young, Jake S. O'Donnell, Stacey Allen, Mark J. Smyth and Michele W.L. TengCancer Discov December 1 2016 6 (12) 1382-1399; DOI:10.1158/2159-8290.CD-16-0577
Neoadjuvant immunotherapy extends survival and reduces metastatic disease more effectively than adjuvant immunotherapy in mouse models of metastatic triple-negative breast cancer.
- ReviewsStanley Zhou, Aislinn E. Treloar and Mathieu LupienCancer Discov November 1 2016 6 (11) 1215-1229; DOI:10.1158/2159-8290.CD-16-0745
- ReviewsKlaus Okkenhaug, Mariona Graupera and Bart VanhaesebroeckCancer Discov October 1 2016 6 (10) 1090-1105; DOI:10.1158/2159-8290.CD-16-0716
- Mini reviewRajarsi Mandal and Timothy A. ChanCancer Discov July 1 2016 6 (7) 703-713; DOI:10.1158/2159-8290.CD-16-0146
- ReviewsJerry W. ShayCancer Discov June 1 2016 6 (6) 584-593; DOI:10.1158/2159-8290.CD-16-0062
News from Cancer Discovery
- “Cures” Act Signed into Law
Bill provides $4.8 billion for NIH and NCI initiatives, including the Beau Biden Cancer Moonshot. - Everolimus Boosts Endocrine Therapy for Breast Cancer
Combining it with fulvestrant doubles progression-free survival in women resistant to aromatase inhibitors. - Abemaciclib Shows Promise for Early Breast Cancer
CDK4/6 inhibitor associated with reduced expression of a key marker of cell proliferation.
OnlineFirst Research Articles & Briefs
- Differential Activity and SERD Sensitivity of ESR1 MutantsWeiyi Toy, et al.
- Venetoclax in Blastic Plasmacytoid Dendritic Cell NeoplasmJoan Montero, et al.
- Cellular Senescence and ChemotherapyMarco Demaria, et al.
- Postpartum Liver Involution and Breast Cancer MetastasisErica T. Goddard, et al.
- Pathways that Drive Luminal B Tumor ProgressionSarah Naomi Olsen, et al.
Advertisement
OnlineFirst Research Watch
A more flexible and intuitive reading experience. Read more about this new feature here, or go to the Lens view of an article to try it out.